secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2021-08-09T23:59:59+00:00
Accession:  0001558370-21-010964
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros Q2 OMIDRIA rev $28.8M (+37% QoQ); narsoplimab PDUFA Oct 17
-----------------------------------------------------------------

- OMIDRIA revenue $28.8M in Q2 2021, up 37% from Q1 $21.1M; net loss narrowed to $28.6M ($0.46/sh) from $35.1M.
- Narsoplimab BLA for HSCT-TMA under FDA priority review with PDUFA action date Oct 17, 2021.
- Preliminary Phase 1 data for OMS906 (MASP-3 inhibitor) show well tolerated, PK/PD consistent with monthly SC dosing.
- CMS proposed rule reaffirms separate payment for OMIDRIA in ASCs for 2022.
- Cash & investments $73.7M; $150M ATM program available; $50M line of credit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000155837021010964/0001558370-21-010964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000155837021010964/omer-20210809x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-010964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer